Moreover, pioglitazone is the only approved PPARγ agonist with significant ability to cross the blood-brain barrier [37, 38] and has demonstrated neuroprotective benefits in models of Alzheimer’s disease, Parkinson’s disease, epilepsy, and stroke [39–42]. Here, PPARG is linked to Stroke.